Your browser doesn't support javascript.
loading
PAX8 and MECOM are interaction partners driving ovarian cancer.
Bleu, Melusine; Mermet-Meillon, Fanny; Apfel, Verena; Barys, Louise; Holzer, Laura; Bachmann Salvy, Marianne; Lopes, Rui; Amorim Monteiro Barbosa, Inês; Delmas, Cecile; Hinniger, Alexandra; Chau, Suzanne; Kaufmann, Markus; Haenni, Simon; Berneiser, Karolin; Wahle, Maria; Moravec, Ivana; Vissières, Alexandra; Poetsch, Tania; Ahrné, Erik; Carte, Nathalie; Voshol, Johannes; Bechter, Elisabeth; Hamon, Jacques; Meyerhofer, Marco; Erdmann, Dirk; Fischer, Matteo; Stachyra, Therese; Freuler, Felix; Gutmann, Sascha; Fernández, César; Schmelzle, Tobias; Naumann, Ulrike; Roma, Guglielmo; Lawrenson, Kate; Nieto-Oberhuber, Cristina; Cobos-Correa, Amanda; Ferretti, Stephane; Schübeler, Dirk; Galli, Giorgio Giacomo.
Afiliação
  • Bleu M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Mermet-Meillon F; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Apfel V; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Barys L; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Holzer L; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bachmann Salvy M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Lopes R; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Amorim Monteiro Barbosa I; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Delmas C; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Hinniger A; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Chau S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Kaufmann M; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Haenni S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Berneiser K; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Wahle M; Biozentrum, University of Basel, Basel, Switzerland.
  • Moravec I; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Vissières A; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Poetsch T; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Ahrné E; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Carte N; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Voshol J; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bechter E; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Hamon J; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Meyerhofer M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Erdmann D; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Fischer M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Stachyra T; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Freuler F; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Gutmann S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Fernández C; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Schmelzle T; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Naumann U; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Roma G; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Lawrenson K; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Nieto-Oberhuber C; Cedars-Sinai Women's Cancer Program at the Samuel Oschin Cancer Center, Los Angeles, CA, USA.
  • Cobos-Correa A; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Ferretti S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Schübeler D; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Galli GG; Friedrich Miescher Institute for Biomedical Research, University of Basel, Basel, Switzerland.
Nat Commun ; 12(1): 2442, 2021 04 26.
Article em En | MEDLINE | ID: mdl-33903593
ABSTRACT
The transcription factor PAX8 is critical for the development of the thyroid and urogenital system. Comprehensive genomic screens furthermore indicate an additional oncogenic role for PAX8 in renal and ovarian cancers. While a plethora of PAX8-regulated genes in different contexts have been proposed, we still lack a mechanistic understanding of how PAX8 engages molecular complexes to drive disease-relevant oncogenic transcriptional programs. Here we show that protein isoforms originating from the MECOM locus form a complex with PAX8. These include MDS1-EVI1 (also called PRDM3) for which we map its interaction with PAX8 in vitro and in vivo. We show that PAX8 binds a large number of genomic sites and forms transcriptional hubs. At a subset of these, PAX8 together with PRDM3 regulates a specific gene expression module involved in adhesion and extracellular matrix. This gene module correlates with PAX8 and MECOM expression in large scale profiling of cell lines, patient-derived xenografts (PDXs) and clinical cases and stratifies gynecological cancer cases with worse prognosis. PRDM3 is amplified in ovarian cancers and we show that the MECOM locus and PAX8 sustain in vivo tumor growth, further supporting that the identified function of the MECOM locus underlies PAX8-driven oncogenic functions in ovarian cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Regulação Neoplásica da Expressão Gênica / Fator de Transcrição PAX8 / Proteína do Locus do Complexo MDS1 e EVI1 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Regulação Neoplásica da Expressão Gênica / Fator de Transcrição PAX8 / Proteína do Locus do Complexo MDS1 e EVI1 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article